Figure 4.
In vitro TTP assay reveals differential drug sensitivities toward ruxolitinib combinations in STAT3- and TP53-mutant cell lines. Concurrent treatment with ruxolitinib and tipifarnib or idasanutlin in STAT3-mutant (A-C) or TP53-mutant (D-F) NK-cell lines. Treatments were maintained for 30 days (gray area) with single drugs and their combinations, and observed for another 30 to 32 days after drug removal (white area). Cells were counted, and drug and media were replenished every third to fourth day and set to 3 to 3.5 × 105 cells/mL cell density. Cultures were stopped when reaching 20 million (2 duplications from start).